DNV GL and Renji Hospital have announced the renewal of their partnership, solidifying their commitment to improving healthcare quality. This partnership, now entering its seventh year, was initially formed in October 2020 when VeChain collaborated with DNV GL and Renji Hospital to launch the Intelligent Tumor Treatment Center powered by blockchain technology.
The main goal of this collaboration was to create a transparent and efficient medical management solution that would allow patients to have control over their medical records. Additionally, authorized data would be made available to internal and external research institutions to enhance clinical research, while regulatory agencies could conduct business compliance checks and credit evaluations on medical institutions.
Senior Vice President of DNV GL Group, George Kang, expressed his enthusiasm for the partnership and the future of healthcare advancements at Renji Hospital. He stated that the launch of the Intelligent Tumor Treatment Center was just the beginning, and more blockchain-powered use cases and projects would be gradually revealed in due time.
Renji Hospital’s partnership with DNV GL dates back to January 2017 when the hospital began the process of certifying its international outpatient program to DNV’s quality standards. After passing the initial evaluation in April 2018, the partnership has now been renewed, showcasing the commitment of both parties to enhancing international medical quality certification.
This collaboration aligns with the Chinese government’s 14th Five-Year Plan for Economic and Social Development, which emphasizes the importance of blockchain technology in the medical and health industry. The National Health Commission has recognized blockchain as a significant innovation and integration into the healthcare sector.
VeChain, together with DNV GL, continues to develop innovative solutions for the medical industry. By leveraging their self-developed VeChain ToolChainTM platform, they have already implemented blockchain-powered solutions in the medical sector, such as the Clinical Trial Traceability Platform for Bayer China and the E-NewHealthLife medical data management platform for the Mediterranean Hospital of Cyprus. With the ongoing digital transformation brought about by COVID-19, VeChain and DNV GL aim to create more efficient and cost-effective digital solutions for the healthcare industry.
